Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 255-449-7 | CAS number: 41583-09-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
There is no study available with melamine phosphate but with melamine.
Melamine was administered to rats in a daily diet over a period of 13 weeks. Melamine induced the formation of urinary calculi in the bladder and hyperplasia in the bladder epithelium of both sexes (NTP 1983). The effects were dose-related, with the male rats being more sensitive than females to the effects in the bladder. The NOAEL of 750 ppm for males (72 mg/kg bw/day) and 15000 ppm for females (1400 mg/kg bw/day) was considered. Later on, the US FDA has recalculated these results to a NOAEL rat,13w, oral of 63 mg/kg bw/day.
Mice were also investigated: The incidence of bladder stones was dose related as in rats, being greater in males than in females, but starting at much higher doses than in rats (NTP 1983).
In a newer subchronic study with monkeys the kidney was also the primary target organ. A NOAEL of 60 mg/kg/d was obtained, much the same as in the rat study, but it should be considered that the study is of poor reliability (Early 2013b).
Key value for chemical safety assessment
- Toxic effect type:
- dose-dependent
Repeated dose toxicity: via oral route - systemic effects
Link to relevant study records
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Justification for type of information:
- For Read Across Justification please refer to section 13.
- Reason / purpose for cross-reference:
- read-across: supporting information
- Reason / purpose for cross-reference:
- read-across source
- Reason / purpose for cross-reference:
- read-across: supporting information
- Reason / purpose for cross-reference:
- read-across: supporting information
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 72 mg/kg bw/day (actual dose received)
- Sex:
- male
- Basis for effect level:
- other: urinary bladder stones/Hyperplasia of bladder epithelium in males
- Remarks on result:
- other: CAS 108-78-1
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 1 400 mg/kg bw/day (actual dose received)
- Sex:
- female
- Basis for effect level:
- other: other: based on the formation of urinary bladder stones and reduced body weights observed in the first study (refers to 15000 ppm)
- Remarks on result:
- other: CAS 108-78-1
- Key result
- Critical effects observed:
- yes
- Lowest effective dose / conc.:
- 1 500 ppm
- System:
- urinary
- Organ:
- bladder
- Treatment related:
- yes
- Dose response relationship:
- yes
- Relevant for humans:
- yes
Reference
Endpoint conclusion
- Dose descriptor:
- NOAEL
- 72 mg/kg bw/day
- Study duration:
- subchronic
- Species:
- rat
- Quality of whole database:
- Thirteen-Week toxicity study, Klimisch 1 (Read Across)
- System:
- urinary
- Organ:
- bladder
- kidney
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Mode of Action Analysis / Human Relevance Framework
The relevant trigger for the toxicity of melamine is the production of urinary tract crystals and calculi at sufficiently high doses, because of the precipitation of melamine in the urine above the solubility limit. Other toxicities observed are considered sequels of the crystals or uroliths. The main toxic effects of melamine are urinary bladder stones and hyperplasia of the transitional epithelium of the bladder in rats, in case uroliths were present. Other effects (lower body weight gain, kidney lesions) were observed at higher doses.
The relevance for humans is low, as no high enough doses has ever been observed to occur in humans to produce bladder calculi, except for the past cases of fraudulent tainting infant formulas in China.
Additional information
There is no study available for melamine phosphate but for melamine, oral studies ranging from 14-day to chronic studies, with rats and mice were reported.
Subchronic studies in rats:
The NTP 1983 13-weeks study with rats is selected as the key repeated dose toxicity studies, as NTP-studies are generally considered to be of high reliability. In this case there are few doubts on the high reliability, as there is an unexpected result for the crucial finding, i.e. urinary bladder stones: There was 1/10 stone in the control group, which is suspicious, as urinary bladder stones in rats are seldom. The results of the chronic study of Reno 1983, see Section 7.7 (NOAEL = 1000 ppm) and subacute study of Heck 1985 (NOAEL = 2000 ppm) are considered to be more appropriate as key studies, but the NTP 13-weeks study with rats was up to now preferred as the worst case study by the health authorities EFSA, WHO, US FDA.
The NTP-studies reported that the main effects of melamine are urinary bladder stones. Hyperplasia of the transitional epithelium of the bladder is detected, in case uroliths were present. These effects occurred in male rats, becoming significant at 1500 ppm in feed (equivalent to 150 mg/kg bw/day), in a dose dependent way. 1/10 stone in the control group and 2/10 stones in the lowest dose of 750 ppm (72 mg/kg/d) were observed. The difference between control and lowest dose is not statistically significant. Other effects (lower body weight gain, kidney lesions) were observed only at ca. 10 times higher doses and above. The NOAEL13weeks, reported by NTP, is 72 mg/kg bw/day, based on urinary stones in male rats (The US FDA has calculated from the same results of the NTP-study a NOELrat,13w,oral of 63 mg/kg bw/day. No data as to how FDA arrived to the result are available). Hard et al. 2009 re-evaluated the histological specimen of the kidneys and detected additional lesions, but only at the highest dose level.
Chronic studies in rats:
A long-term NOAEL of 2250 ppm, corresponding to ca. 126 mg melamine/kg bw/day, was derived from the NTP 1983 2-years study for male rats, see section 7.7. Interestingly enough, the 5 bladder stones detected in 10 animals in the 13-weeks study at 1500 ppm were not anymore detected at the even higher dose of 2250 ppm at the end of the 2-years study, as only 1 rat out of 50 dosed rats had a bladder stone. A regression of bladder stones occurs with time, even at ongoing dosing. Hard et al. 2009 re-evaluated the histological specimen of the kidneys and detected retrograde nephropathy in 7 out of 50 rats in the low dose group (2250 ppm), turning the NOAEL of 2250 ppm into a LOAEL.
A chronic study with rats and with doses at the lower end of the NTP-study was performed by Reno 1985, see Section 7.7. The NOAEL was 1000 ppm for male and 2000 ppm for female rats.
Subacute studies in rats:
- The NOAEL of the NTP 1983 14-days study with rats is 417 mg/kg bw/d.
NOAELs in relation to the exposure duration for rats are:
14 days: 417 mg/kg bw/day
28 days. 240 mg/kg bw/day
13 weeks: 72 respectively 63 mg/kg bw/day
2 years: LOAEL = 126 mg/kg bw/day
The LOAELrat, 2 years, oral of 126 mg/kg bw/day was taken as - worst case - basis for the calculation of the long-term DNEL of melamine phosphate.
Based on the differences in molecular weight (MW of melamine phosphate = 224.1 g/mol) and the fact that melamine represents the toxicologically relevant part of the compound, this LOAEL could be adapted to 224.28 mg/kg bw/d. It is expected that the formation of crystals in the urinary tract start at higher doses of melamine phosphate compared to melamine alone. However, the LOAEL for melamine is taken forward for DNEL calculation for precautionary reasons, giving a high margin of safety.
Mice: Mice were also investigated by NTP 1983. The incidence of bladder stones was dose related as in rats, being greater in males than in females, starting at much higher doses of 12000 mg/kg feed.
Monkey: In a subchronic study with monkeys (Early 2013), the kidneys were again the primary target organ. A NOAEL of 60 mg/kg/d was derived, much the same as in the rat study. The study has a poor reliability.
Justification for classification or non-classification
Classification, Labelling, and Packaging Regulation (EC) No. 1272/2008:
Based on the data available, melamine phosphate is not classified for repeated dose toxicity under Regulation (EC) No.1272/2008 (CLP)
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.